Treshita Dey

Treshita Dey

Auto-generated profile, based on publicly available information

Treshita Dey

Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Global Health
Verified
Journal Article
Closed access
DKDivyesh Kumar
Divyesh Kumar
TDTreshita Dey
Treshita Dey

2 March 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
TDTreshita Dey
Treshita Dey
SAsushma agrawal
sushma agrawal
Cervical cancer remains a significant global health challenge, ranking as the fourth most common cancer among women. Persistent infection with high-risk human papillomavirus (HPV) is the primary etiological factor, leading to immune evasion mechanisms that promote tumor development and progression. Immunotherapy has emerged as a transformative approach in the management of cervical cancer, aiming to restore and enhance the body’s immune response against tumor cells. Checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1) have shown promising results in patients with advanced or recurrent cervical cancer. Pembrolizumab, a PD-1 inhibitor, has been approved for PD-L1-positive cervical cancer, demonstrating durable responses. However, low response rates necessitate exploration of combination strategies. Trials are underway combining checkpoint inhibitors with chemotherapy, radiation, or other immunotherapeutic agents to enhance efficacy. Therapeutic vaccines targeting HPV antigens, such as E6 and E7 oncoproteins, are also a focus of active research. These vaccines aim to elicit robust cytotoxic T-cell responses, offering a potential strategy for early intervention and disease control. Adoptive T-cell therapies, including engineered T-cell receptor (TCR) and chimeric antigen receptor (CAR)-T cells, represent cutting-edge advancements, though challenges with tumor heterogeneity and off-target effects persist. However, challenges such as limited response rates and immune evasion mechanisms remain. The tumor microenvironment (TME) in cervical cancer, characterized by immunosuppressive cells and cytokines, poses a significant barrier to effective immunotherapy. Emerging approaches targeting the TME, such as cytokine modulation, hold promise in overcoming resistance mechanisms. Key gaps include a lack of biomarkers for patient selection, insufficient understanding of TME dynamics, and suboptimal strategies for overcoming antigen heterogeneity and immune resistance. This review addresses these issues by providing a comprehensive analysis of the current landscape of cervical cancer immunotherapy, identifying critical barriers, and highlighting emerging approaches, such as combination therapies, novel immune targets, and strategies to modulate the TME, to guide future research and clinical practice.

3 June 2020 in Journal of Public Health
Verified
Journal Article
Closed access
BNBada Sharanappa Nagaraja
Bada Sharanappa Nagaraja
KRKalhalli Narayanaswamy Ramesh
Kalhalli Narayanaswamy Ramesh
DDDebjyoti Dhar
Debjyoti Dhar
MSMM Samim
MM Samim
TDTreshita Dey
Treshita Dey
VSVikram Singh
Vikram Singh
Background: The rising burden of Coronavirus disease (COVID-19) has led to the mass use of hydroxychloroquine by healthcare workers (HCWs). Adverse event profile of this drug when used as prophylaxis is not well known in the literature. Methods: A retrospective, cross-sectional study was conducted across the country using semi-structured web-based questionnaire among COVID-19 negative and asymptomatic healthcare workers, taking hydroxychloroquine prophylaxis. Descriptive and multivariate logistic-regression models were applied for analysis. Results: Of the 166 participants, at least one adverse event was experienced by 37.9% participants, gastrointestinal being the most common (30.7%). Risk was higher in participants <40 years age (odd’s ratio (OR): 2.44, 95% confidence interval (CI): 1.18–5.05) and after first dose of hydroxychloroquine (51.2%, OR: 2.38, 95%CI: 1.17–4.84). Hydroxychloroquine prophylaxis was initiated without electrocardiography by 80.1% of HCWs. Only 21.6% of those with cardiovascular disease could get prior ECG. Conclusions: A higher incidence of adverse events was observed when results were compared with studies involving patients on long-term hydroxychloroquine therapy. Younger age and first dose were associated with greater incidence of adverse events though all were self-limiting. Monitoring prior and during prophylaxis was inadequate even among those with cardiovascular disease and risk-factors. However, no serious cardiovascular events were reported.

27 October 2022 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
MSMM Samim
MM Samim
DDDebjyoti Dhar
Debjyoti Dhar
SGSheetal Goyal
Sheetal Goyal
TDTreshita Dey
Treshita Dey
NPNaznin Parvin
Naznin Parvin
SSShahyan Siddiqui
Shahyan Siddiqui
Samim M, et al. J Clin Neurol. 2022 Nov;18(6):692-710. https://doi.org/10.3988/jcn.2022.18.6.692

10 March 2022 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
SGSushmita Ghoshal
Sushmita Ghoshal
MAMinni Arora
Minni Arora
ACAdrija Chakrabarti
Adrija Chakrabarti
ADAvradeep Datta
Avradeep Datta
TDTreshita Dey
Treshita Dey
A cross-sectional study was planned to assess the socio-economic burden of cancer among patients referred for palliative care. Patients referred within 6 months of diagnosis were grouped as early while others were late referrals. The socio-economic status, out-of-pocket expenditure (OOPE), and budget adjustments were noted and compared between the two groups using SPSS v 23.0. A total of 96 patients were included among which 57 were referred late. Most patients belonged to middle- and lower-income groups but only 22/96 had some kind of social security. The demographic profiles of the two groups were comparable. Although the patients referred late had more OOPE compared to the early ones, the difference was not statistically significant. Patients receiving chemotherapy had a significantly higher OOPE (P = 0.001). Job interruptions and loss of family income leading to budget adjustments were reported by 50 patients. The study indicates that there is a significant economic impact and OOPE that needs to be addressed in our patient population.

6 July 2024 in Innovative Practice in Breast Health
Verified
Journal Article
Open access
RKRAKESH KAPOOR
RAKESH KAPOOR
TDTreshita Dey
Treshita Dey
DKDivya Khosla
Divya Khosla
ILIshita Laroiya
Ishita Laroiya